CA-CEPTON-TECHNOLOGIES
5.10.2021 15:02:11 CEST | Business Wire | Press release
Cepton Technologies (“Cepton”), an innovative provider of smart lidar solutions , and Vortex IoT (“Vortex”), a UK-based IoT solutions company, have combined their skills to turn UK buses into real-time road inspection tools, enabling a lidar-based vehicle to infrastructure (V2I) solution for urban asset management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005421/en/
Vortex’s award-winning lidar-powered Continuous Urban Scanner System (CURBS ) enables asset and infrastructure management by identifying certain situations such as pot-holes, surface damage and roadside defects in real time by using 5G wireless technology to transmit the data to road management teams.
This solution uses artificial intelligence and machine learning alongside Cepton’s Vista®-P60 high-resolution lidar sensors to create a detailed map of the urban environment. This is done by retrofitting the CURBS product to vehicles to create a real-time 3D scanning and dynamic monitoring system. Mounted on public transportation, such as bus fleets, refuse collection trucks and mobile enforcement vehicles, the lidar-embedded CURBS product is able to pinpoint areas that may need repair to maintenance teams, allowing for the early identification of issues.
CURBS streams the processed information over 5G networks. Crucially, this information helps to not only provide real-time insights to services such as road maintenance, but also to drive intelligent decisions with the goal of optimizing traffic management, such as enabling preventive measures in accident-prone areas and improving the efficiency of traffic. These anticipated improvements are intended to ultimately help drive down carbon emission while making cities safer and smarter.
A pilot for the solution is currently underway in the West Midlands in a UK Government-sponsored 5G program called “WM5G”, where Vortex has partnered with National Express and BT.
“The mission of the WM5G Transport team is to support 5G innovation within the region to make transport networks safer, more sustainable and more intuitive to users,” said David Conner, Project manager at WM5G Transport. “The CURBS project is a great example of how the West Midlands is leading the way nationally in making our cities smarter and better connected. By enabling powerful connectivity to transfer large amounts of lidar and camera data, 5G supports the generation of 3D maps capable of providing the insights required to enhance road safety and guide the development of smart cities.”
Vortex also has additional deployments scheduled with traffic enforcement and smart city management company, Marston Holdings.
“With vehicles becoming increasingly smarter, city infrastructure also demands next-generation innovations to deliver matching intelligence. Smart city solutions like CURBS are set to become commonplace across our towns and cities,” said Adrian Sutton, co-founder and CEO at Vortex.
“Public authorities need efficient, scalable ways to manage urban environments, and this becomes even more important as the focus on issues such as decarbonization, sustainability and climate change grows.”
“At the heart of this is digital transformation and the potential that connected technologies and data analytics present for asset management in real time. Enhanced use of big data will drive rapid urban planning and dynamic decision making. Here, perception is key, and nothing can produce accurate 3D data in real-life urban environments quite like lidar – especially the state-of-the-art lidar solutions developed by Cepton, which combine high resolution and long range while enabling sensor robustness and reliability, making their sensors ideally suited for these types of applications.”
CURBS leverages a number of benefits through its use of Cepton’s Vista-P60 sensors . Firstly, the lidars perform with accuracy and resilience in a variety of weather and lighting conditions. In contrast, cameras need sufficient light to be effective and can be blinded by strong light. Because cameras provide only two-dimensional imaging typically with no accurate size and location data, they need additional computing resource to process the image to extract useful information, which might take up more bandwidth and lead to lag.
Secondly, lidar data is completely anonymized , protecting the privacy of citizens and eliminating the need for additional data management and security protocols. Lidar collects no biometric data, making individual features unidentifiable from lidar point cloud visualizations.
Finally, the Vista-P60 lidars, powered by Cepton’s patented Micro Motion Technology (MMT®), are non-rotational, mirrorless and frictionless . This makes it possible for the sensor to deliver high performance while offering a low-power and compact solution to help drive down integration and maintenance costs. The scalability of the Vista-P60 lidars make them ideal for V2I smart city applications like CURBS.
Dr. Jun Pei, CEO at Cepton, explained: “Advanced sensor technologies have played an increasingly important role in the development of safe, accurate and intelligent transportation systems . Using our MMT-based lidar solutions, we are pleased to partner with Vortex to enable CURBS to achieve its mission of helping towns and cities across the world become safer, greener and more efficient for all.”
Cepton will participate in the upcoming ITS World Congress 2021 in Hamburg, Germany from October 11th to 15th . To learn more about Cepton’s partnership with Vortex and its lidar solutions for smart cities applications, please visit booth B7-135 .
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About Vortex IoT
Vortex is a young, dynamic and market-leading company at the forefront of smart city technologies. The company builds environmental sensors, networks and data solutions to support decarbonisation efforts globally. As experts in the latest IoT, AI, 5G and LiDAR technology, Vortex enables smart cities & smart infrastructures to become more efficient, safer and greener.
Monitor what matters; Act where it counts. Vortex's sensor technology aims to maximize visibility and delivers the actionable data that businesses need to start making smarter decisions. Air Quality Monitoring, Vehicle-2-Infrastructure Scanning, Remote Infrastructure Management and Smart Parking Systems are Vortex's tailored solutions for progressive smart city management. Powered by AI and enabled by a highly secure decentralised mesh network, all of Vortex’s products guarantee reliability, scalability and environmentally sustainable deployments.
Founded upon a bedrock of innovation, Vortex’s highly skilled team of engineers, technologists and leadership team are constantly developing the eco-smart products of tomorrow, for you today. For more information, please visit www.vortexiot.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005421/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
